Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery

Protein Expression and Purification

Volumn 71, Issue 1, 2010, Pages 62-73

  Band, Philip A ^a   Blais, Steven ^a   Neubert, Thomas A ^a   Cardozo, Timothy J ^a   Ichtchenko, Konstantin ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Baculovirus; Botulinum neurotoxin A; Clostridium botulinum; Protease; Sfp phosphopantetheinyl transferase

Indexed keywords

BOTULINUM TOXIN A; FLUORESCENT DYE; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; MUTANT PROTEIN; PEPTIDE;

AMINO ACID SEQUENCE; ARTICLE; CHEMISTRY; ELECTROSPRAY MASS SPECTROMETRY; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; NERVE CELL; PROTEIN ENGINEERING; PROTEIN PROCESSING; PROTEIN TRANSPORT;

AMINO ACID SEQUENCE; BOTULINUM TOXIN TYPE A; FLUORESCENT DYES; GREEN FLUORESCENT PROTEINS; MOLECULAR SEQUENCE DATA; MUTANT PROTEINS; NEURONS; PEPTIDES; PROTEIN ENGINEERING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; RECOMBINANT FUSION PROTEINS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

CLOSTRIDIUM BOTULINUM;

EID: 77049097581     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2009.12.013     Document Type: Article

References (40)

1. National Institute of Occupational Safety and Health, Registry of Toxic Effects of Chemical Substances (R-TECS), National Institute of Occupational Safety and Health, Cincinnati, Ohio, 1996.
2. Smith T.J., Lou J., Geren I.N., Forsyth C.M., Tsai R., Laporte S.L., Tepp W.H., Bradshaw M., Johnson E.A., Smith L.A., and Marks J.D. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect. Immun. 73 9 (2005) 5450-5457
3. Simpson L.L. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 44 (2004) 167-193
4. Koriazova L.K., and Montal M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat. Struct. Biol. 10 1 (2003) 13-18
5. Dekleva M.L., DasGupta B.R., and Sathyamoorthy V. Botulinum neurotoxin type A radiolabeled at either the light or the heavy chain. Arch. Biochem. Biophys. 274 1 (1989) 235-240
6. Zhou L., de Paiva A., Liu D., Aoki R., and Dolly J.O. Expression and purification of the light chain of botulinum neurotoxin A: a single mutation abolishes its cleavage of SNAP-25 and neurotoxicity after reconstitution with the heavy chain. Biochemistry 34 46 (1995) 15175-15181
7. Goodnough M.C., Oyler G., Fishman P.S., Johnson E.A., Neale E.A., Keller J.E., Tepp W.H., Clark M., Hartz S., and Adler M. Development of a delivery vehicle for intracellular transport of botulinum neurotoxin antagonists. FEBS Lett. 513 (2002) 163-168
8. Toth S.I., Smith L.A., and Ahmed S.A. Extreme sensitivity of botulinum neurotoxin domains towards mild agitation. J. Pharm. Sci. 98 9 (2009) 3302-3311
9. Kiyatkin N., Maksymowych A.B., and Simpson L.L. Induction of an immune response by oral administration of recombinant botulinum toxin. Infect. Immun. 65 (1997) 4586-4591
10. C-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol. Microbiol. 51 3 (2004) 631-643
11. Rummel A., Karnath T., Henke T., Bigalke H., and Binz T. Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. J. Biol. Chem. 279 29 (2004) 30865-30870
12. Bade S., Rummel A., Reisinger C., Karnath T., Ahnert-Hilger G., Bigalke H., and Binz T. Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurons via unfolded translocation intermediates. J. Neurochem. 91 6 (2004) 1461-1472
13. Pier C.L., Tepp W.H., Bradshaw M., Johnson E.A., Barbieri J.T., and Baldwin M.R. Recombinant holotoxoid vaccine against botulism. Infect. Immun. 76 1 (2008) 437-442
14. Webb R.P., Smith T.J., Wright P., Brown J., and Smith L.A. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. Vaccine 27 33 (2009) 4490-4497
15. Thompson D.E., Brehm J.K., Oultram J.D., Swinfield T.J., Shone C.C., Atkinson T., Melling J., and Minton N.P. The complete amino acid sequence of the Clostridium botulinum type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene. Eur. J. Biochem. 189 1 (1990) 73-81
16. Zhou Z., Cironi P., Lin A.J., Xu Y., Hrvatin S., Golan D.E., Silver P.A., Walsh C.T., and Yin J. Genetically encoded short peptide tags for orthogonal protein labeling by Sfp and AcpS phosphopantetheinyl transferases. ACS Chem. Biol. 2 5 (2007) 337-346
17. Yin J., Lin A.J., Golan D.E., and Walsh C.T. Site-specific protein labeling by Sfp phosphopantetheinyl transferase. Nat. Protoc. 1 1 (2006) 280-285
18. Shevchenko A., Jensen O.N., Podtelejnikov A.V., Sagliocco F., Wilm M., Vorm O., Mortensen P., Shevchenko A., Boucherie H., and Mann M. Linking genome and proteome by mass spectrometry: large-scale identification of yeast proteins from two dimensional gels. Proc. Natl. Acad. Sci. USA 93 25 (1996) 14440-14445
19. Sano K., Maeda K., Oki M., and Maéda Y. Enhancement of protein expression in insect cells by a lobster tropomyosin cDNA leader sequence. FEBS Lett. 532 1-2 (2002) 143-146
20. von Heijne G. Signals for protein targeting into and across membranes. Subcell. Biochem. 22 (1994) 1-19
21. Baldwin M.R., Bradshaw M., Johnson E.A., and Barbieri J.T. The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability. Protein Expr. Purif. 37 1 (2004) 187-195
22. Brunger A.T., Breidenbach M.A., Jin R., Fischer A., Santos J.S., and Montal M. Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PLoS Pathog. 3 9 (2007) 1191-1194 e113
23. Fischer A., Mushrush D.J., Lacy D.B., and Montal M. Botulinum neurotoxin devoid of receptor binding domain translocates active protease. PLoS Pathog. 4 12 (2008) 1-9 e1000245
24. Ahmed S.A., and Smith L.A. Light chain of botulinum A neurotoxin expressed as an inclusion body from a synthetic gene is catalytically and functionally active. J. Protein Chem. 19 6 (2000) 475-487
25. 6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain. Protein Expr. Purif. 34 1 (2004) 8-16
26. Lacy D.B., and Stevens R.C. Recombinant expression and purification of the botulinum neurotoxin type A translocation domain. Protein Expr. Purif. 11 2 (1997) 195-200
27. Ichtchenko K., and Band P.A. Full-length Clostridium botulinum serotype A derivatives with native structure and properties. Neurotox. Res. 9 (2006) 234
28. Li Y., Foran P., Lawrence G., Mohammed N., Chan-Kwo-Chion C.K., Lisk G., Aoki R., and Dolly O. Recombinant forms of tetanus toxin engineered for examining and exploiting neuronal trafficking pathways. J. Biol. Chem. 276 33 (2001) 31394-31401
29. DasGupta B.R., and Dekleva M.L. Botulinum neurotoxin type A: sequence of amino acids at the N-terminus and around the nicking site. Biochimie 72 9 (1990) 661-664
30. Krieglstein K.G., DasGupta B.R., and Henschen A.H. Covalent structure of botulinum neurotoxin type A: location of sulfhydryl groups, and disulfide bridges and identification of C-termini of light and heavy chains. J. Protein Chem. 13 1 (1994) 49-57
31. Shone C.C., Hambleton P., and Melling J. Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments. Proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity. Eur. J. Biochem. 151 1 (1985) 75-82
32. Chaddock J.A., Herbert M.H., Ling R.J., Alexander F.C., Fooks S.J., Revell D.F., Quinn C.P., Shone C.C., and Foster K.A. Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A. Protein Expr. Purif. 25 2 (2002) 219-228
33. Rigoni M., Caccin P., Johnson E.A., Montecucco C., and Rossetto O. Site-directed mutagenesis identifies active-site residues of the light chain of botulinum neurotoxin type A. Biochem. Biophys. Res. Commun. 288 5 (2001) 1231-1237
34. Li L., Binz T., Niemann H., and Singh B.R. Probing the mechanistic role of glutamate residue in the zinc-binding motif of type A botulinum neurotoxin light chain. Biochemistry 39 9 (2000) 2399-2405
35. Lacy D.B., Tepp W., Cohen A.C., DasGupta B.R., and Stevens R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 5 10 (1998) 898-902
36. Fernandez-Salas E., Steward L.E., Ho H., Garay P.E., Sun S.W., Gilmore M.A., Ordas J.V., Wang J., Francis J., and Aoki K.R. Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc. Natl. Acad. Sci. USA 101 9 (2004) 3208-3213
37. Grumelli C., Verderio C., Pozzi D., Rossetto O., Montecucco C., and Matteoli M. Internalization and mechanism of action of clostridial toxins in neurons. Neurotoxicology 26 5 (2005) 761-767
38. Ahsan C.R., Hajnóczky G., Maksymowych A.B., and Simpson L.L. Visualization of binding and transcytosis of botulinum toxin by human intestinal epithelial cells. J. Pharmacol. Exp. Ther. 315 3 (2005) 1028-1035
39. Taki M., Shiota M., and Taira K. Transglutaminase-mediated N- and C-terminal fluorescein labeling of a protein can support the native activity of the modified protein. Protein Eng. Des. Sel. 17 2 (2004) 119-126
40. Bouvier A., Chapline J., Boerner R., Jeyarajah S., Cook S., Acharya P.S., Henderson I., Schrimsher J.L., and Shepard S.R. Identifying and modulating disulfide formation in the biopharmaceutical production of a recombinant protein vaccine candidate. J. Biotechnol. 103 3 (2003) 257-271